| 序号 | 专利名 | 申请号 | 申请日 | 公开（公告）号 | 公开（公告）日 | 发明人 |
|---|---|---|---|---|---|---|
| 21 | ＭＡＰＫ阻害剤 | JP2017530367 | 2015-08-25 | JP2017525770A | 2017-09-07 | ワン，ビン，フイ; クルム，ヘンリー; スキャメルス，ピーター; ビン，ナタリー; シンプソン，ジェイミー; チャルマース，デーヴィッド |
| 本発明は、特定の新規な置換性チオフェン化合物、及び置換性チオフェン化合物がp38αMAPK酵素の抑制下、有利な効果を示す知見に関する。これは、炎症治療を含むMAPK抑制に関連する種々の処置法に本化合物の使用法を備えるものである。【選択図】図1 | ||||||
| 22 | Substituted alkyl amine derivatives and methods of use of it | JP2002565984 | 2002-01-11 | JP4408627B2 | 2010-02-03 | アダムズ，ジエフリー; エルバウム，ダニエル; オウヤン，シヤオフー; カイ，クオリン; キセリヨフ，アレクサンダー; キム，ジヨウゼフ・エル; キム，テ−ソン; クローガン，マイケル; ゲウンス−マイヤー，ステフアニー; シー，ニン; シウ，シミン; ジエルマン，ジユリー; ステツク，マーキアン; スミス，レオン・エム; タスカー，アンドリユー; チエン，クオチン; デイピエトロ，ルシアン; ドミンゲス，セリア; パテル，ビノード・エフ; ハンドリー，マイケル; ビーミス，ジーン; ブツカー，シヨーン; ホワン，チー; ユアン，チエスター・チエンクワン |
| 23 | Imidazole hydrazone derivative | JP890381 | 1981-01-23 | JPS56150069A | 1981-11-20 | PIITAA JIYON FUERUNAA; BURENDAN JIEEMUSU HAMIRU; POORU UIRIAMU MANRII |
| 24 | MAPK INHIBITORS | EP15835823 | 2015-08-25 | EP3186245A4 | 2018-01-10 | KRUM HENRY; SCAMMELLS PETER; VINH NATALIE; SIMPSON JAMIE; CHALMERS DAVID; WANG BING HUI |
| The present invention relates to certain novel substituted thiophene compounds and the finding that they display useful efficacy in the inhibition of the p38α MAPK enzyme. This provides for use of the compounds in various treatment methodologies related to MAPK inhibition, including the treatment of inflammation. | ||||||
| 25 | Substituted alkylamine derivatives and methods of use | EP10176821.6 | 2002-01-11 | EP2311829A1 | 2011-04-20 | Chen, Guoqung; Adams, Jeffrey; Bemis, Jean; Booker, Shon; Cai, Guolin; Croghan, Michael; Dipietro, Lucian; Dominguez, Celia; Elbaum, Daniel; Germain, Julie; Geuns-Meyer, Stephanie; Handley, Michael; Huang, Qi; Kim, L. Joseph; Kim, Tae-Seong; Kiselyov, Alexander; Ouyang, Xiaohu; Patel, Vinod, F.; Smith, Leon, M.; Markian, Stec; Tasker, Andrew; Xi, Ning; Xu, Shimin; Yuan, Chester, Chenguang |
Selected heterocyclic compounds are effective for prophylaxis and treatment of diseases, such as angiogenesis mediated diseases. The invention encompasses novel compounds, analogs, prodrugs and pharmaceutically acceptable derivatives thereof, pharmaceutical compositions and methods for prophylaxis and treatment of diseases and other maladies or conditions involving, cancer and the like. The subject invention also relates to processes for making such compounds as well as to intermediates useful in such processes. |
||||||
| 26 | N-(3,3-Dimethylindolin-6-yl){2-[(4-pyridylmethyl)amino}(3-pyridyl)}carboxamide and pharmaceutical compositions thereof. | EP02717325.1 | 2002-01-11 | EP1358184B1 | 2007-05-02 | CHEN, Guoqing; ADAMS, Jeffrey; BEMIS, Jean; BOOKER, Shon; CAI, Guolin; CROGHAN, Michael; DIPIETRO, Lucian; DOMINGUEZ, Celia; ELBAUM, Daniel; GERMAIN, Julie; GEUNS-MEYER, Stephanie; HANDLEY, Michael; HUANG, Qi; KIM, Joseph, L.; KIM, Tae-Seong; KISELYOV, Alexander; OUYANG, Xiaohu; PATEL, Vinod, F.; SMITH, Leon, M.; STEC, Markian; TASKER, Andrew; XI, Ning; XU, Shimin; YUAN, Chester Chenguang |
| Selected heterocyclic compounds are effective for prophylaxis and treatment of diseases, such as angiogenesis mediated diseases. The invention encompasses novel compounds, analogs, prodrugs and pharmaceutically acceptable derivatives thereof, pharmaceutical compositions and methods for prophylaxis and treatment of diseases and other maladies or conditions involving, cancer and the like. The subject invention also relates to processes for making such compounds as well as to intermediates useful in such processes. | ||||||
| 27 | 치환된 알킬아민 유도체 및 그의 사용 방법 | KR1020037009274 | 2002-01-11 | KR1020030078067A | 2003-10-04 | 첸,구오킹; 아담스,제프리; 베미스,진; 부커,숀; 카이,구올린; 크로간,마이클; 디피에트로,루시안; 도밍궤즈,셀리아; 엘바움,다니엘; 저메인,줄리; 쥔스-마이어,스테파니; 핸들리,마이클; 후앙,키; 킴,조세프,엘.; 김,태-성; 키젤료브,알렉산더; 오우양,샤오후; 파텔,비노드에프.; 스미스,레온,엠.; 스텍,마르키안; 태스커,앤드류; 시,닝; 슈,쉬민; 유안,체스터,첸구앙 |
| 선택된 헤테로시클릭 화합물은 혈관생성 관련 질환과 같은 질환의 예방 및 치료에 효과적이다. 본 발명은 신규 화합물, 유사체, 전구약물(prodrug) 및 그의 약학적으로 허용가능한 유도체, 제약 조성물 및 암 등과 관련된 증상 또는 기타 질환 및 질병을 예방 및 치료하는 방법을 포함한다. 본 발명은 또한 상기 화합물을 제조하는 방법 및 상기 방법에 유용한 중합체에 관한 것이다. | ||||||
| 28 | 생체적합성 형광 나노입자 및 이의 용도 | KR1020140067102 | 2014-06-02 | KR1020150138726A | 2015-12-10 | 김세훈; 권익찬; 이상엽 |
| 본발명은신규한쌍극성아릴비닐화합물, 이를포함하는나노프로브입자, 그리고이를이용한조영제조성물및 이미징방법에관한것이다. 본발명의쌍극성아릴비닐화합물은생리학적조건에서고체-상나노응집체들을형성하여증가된 SSF 및 AEF를나타낼뿐 아니라공여체-수용체조합에따라 SSF 색의조정이가능하고, 수용성환경에서약 65 nm 미만의유체역학적크기를나타낸다. 본발명의나노프로브입자는약 25 nm 미만의유체역학적크기를가지고, 650 nm 이상의근적외선(near-infrared, NIR) 영역에서증가된 SSF를나타내며, 특정조직(예컨대, 감시림프절, 종양또는뇌)에세포또는레벨에서축적됨에따라상기조직을특이적으로검출하는데 이용할수 있다. 따라서, 본발명의나노프로브입자를포함하는조영제조성물및 이미징방법은림프절, 종양또는뇌 조직을특이적으로조영할수 있다는점에서암/종양또는뇌 질환의진단에효율적으로적용될수 있다. | ||||||
| 29 | MAPK INHIBITORS | EP15835823.4 | 2015-08-25 | EP3186245A1 | 2017-07-05 | KRUM, Henry; SCAMMELLS, Peter; VINH, Natalie; SIMPSON, Jamie; CHALMERS, David; WANG, Bing Hui |
| The present invention relates to certain novel substituted thiophene compounds and the finding that they display useful efficacy in the inhibition of the p38α MAPK enzyme. This provides for use of the compounds in various treatment methodologies related to MAPK inhibition, including the treatment of inflammation. | ||||||
| 30 | CRYSTALLINE AND NON-CRYSTALLINE FORMS OF SGLT2 INHIBITORS | EP12846707.3 | 2012-10-30 | EP2773359A2 | 2014-09-10 | HO, Meng-Fen; CHEN, Shu-Ping; CHEN, Yung-Fa |
| The present invention provides amorphous forms and the crystalline complexes of SGLT2 inhibitors as a novel material, in particular in pharmaceutically acceptable form. The crystalline forms of SGLT2 inhibitor canagliflozin are designated as Forms CS1, CS2, CS3, CS4 and CS5. | ||||||
| 31 | Substituted alkylamine derivatives and methods of use | EP10176822.4 | 2002-01-11 | EP2311808A1 | 2011-04-20 | Chen, Guoqung; Adams, Jeffrey; Bernis, Jean; Booker, Shon; Cai, Guolin; Croghan, Michael; Dipietro, Lucian; Dominguez, Celia; Elbaum, Daniel; Germain, Julie; Geuns-Meyer, Stephanie; Handley, Michael; Huang, Qi; Kim, L. Joseph; Kim, Tae-Seong; Kiselyov, Alexander; Ouyang, Xiaohu; Patel, F. Vinod; Smith, M. Leon; Stec, Markian; Tasker, Andrew; Xi, Ning; Xu, Shimin; Yuan, Chenguan Chester |
Selected heterocyclic compounds are effective for prophylaxis and treatment of diseases, such as angiogenesis mediated diseases. The invention encompasses novel compounds, analogs, prodrugs and pharmaceutically acceptable derivatives thereof, pharmaceutical compositions and methods for prophylaxis and treatment of diseases and other maladies or conditions involving, cancer and the like. The subject invention also relates to processes for making such compounds as well as to intermediates useful in such processes. |
||||||
| 32 | Substituted alkylamine derivatives and methods of use | EP07003413.7 | 2002-01-11 | EP1798230A1 | 2007-06-20 | Chen, Guoqing; Adams, Jeffrey; Bemis, Jean; Booker, Shon; Cai, Guolin; Croghan, Michael; Dipietro, Lucian; Dominguez, Celia; Elbaum, Daniel; Germain, Julie; Geuns-Meyer, Stephanie; Handley, Michael; Huang, Qi; Kim, L. Joseph; Kim, Tae-Seong; Kiselyov, Alexander; Ouyang, Xiaohu; Patel, Vinod, F.; Smith, Leon, M.; Stec, Markian; Tasker, Andrew; Xi, Ning; Xu, Shimin; Yuan, Chester, Chenguang |
Selected heterocyclic compounds are effective for prophylaxis and treatment of diseases, such as angiogenesis mediated diseases. The invention encompasses novel compounds, analogs, prodrugs and pharmaceutically acceptable derivatives thereof, pharmaceutical compositions and methods for prophylaxis and treatment of diseases and other maladies or conditions involving, cancer and the like. The subject invention also relates to processes for making such compounds as well as to intermediates useful in such processes. |
||||||
| 33 | SUBSTITUTED ALKYLAMINE DERIVATIVES AND METHODS OF USE | EP02717325.1 | 2002-01-11 | EP1358184A1 | 2003-11-05 | CHEN, Guoqing; ADAMS, Jeffrey; BEMIS, Jean; BOOKER, Shon; CAI, Guolin; CROGHAN, Michael; DIPIETRO, Lucian; DOMINGUEZ, Celia; ELBAUM, Daniel; GERMAIN, Julie; GEUNS-MEYER, Stephanie; HANDLEY, Michael; HUANG, Qi; KIM, Joseph, L.; KIM, Tae-Seong; KISELYOV, Alexander; OUYANG, Xiaohu; PATEL, Vinod, F.; SMITH, Leon, M.; STEC, Markian; TASKER, Andrew; XI, Ning; XU, Shimin; YUAN, Chester Chenguang |
| Selected heterocyclic compounds are effective for prophylaxis and treatment of diseases, such as angiogenesis mediated diseases. The invention encompasses novel compounds, analogs, prodrugs and pharmaceutically acceptable derivatives thereof, pharmaceutical compositions and methods for prophylaxis and treatment of diseases and other maladies or conditions involving, cancer and the like. The subject invention also relates to processes for making such compounds as well as to intermediates useful in such processes. | ||||||
| 34 | SGLT2 억제제의 결정성 및 비-결정성 형태 | KR1020147014572 | 2012-10-30 | KR1020140097258A | 2014-08-06 | 헨쉬케,줄리안파울; 호,멩-펜; 첸,슈-핑; 첸,영-파 |
| 본 발명은 신규한 물질, 특히 약학적으로 허용되는 형태로서의 SGLT2 억제제의 무정형 형태 및 결정성 복합체를 제공한다. SGLT2 억제제 카나글리플로진의 결정성 형태는 형태 CS1, CS2, CS3, CS4 및 CS5로 명명된다. | ||||||
| 35 | 치환된 알킬아민 유도체 및 그의 사용 방법 | KR1020037009274 | 2002-01-11 | KR100848429B1 | 2008-07-28 | 첸,구오킹; 아담스,제프리; 베미스,진; 부커,숀; 카이,구올린; 크로간,마이클; 디피에트로,루시안; 도밍궤즈,셀리아; 엘바움,다니엘; 저메인,줄리; 쥔스-마이어,스테파니; 핸들리,마이클; 후앙,키; 킴,조세프,엘.; 김,태-성; 키젤료브,알렉산더; 오우양,샤오후; 파텔,비노드에프.; 스미스,레온,엠.; 스텍,마르키안; 태스커,앤드류; 시,닝; 슈,쉬민; 유안,체스터,첸구앙 |
| 선택된 헤테로시클릭 화합물은 혈관생성 관련 질환과 같은 질환의 예방 및 치료에 효과적이다. 본 발명은 신규 화합물, 유사체, 전구약물(prodrug) 및 그의 약학적으로 허용가능한 유도체, 제약 조성물 및 암 등과 관련된 증상 또는 기타 질환 및 질병을 예방 및 치료하는 방법을 포함한다. 본 발명은 또한 상기 화합물을 제조하는 방법 및 상기 방법에 유용한 중합체에 관한 것이다. 치환된 알킬아민, 혈관생성 | ||||||
| 36 | CRYSTALLINE AND NON-CRYSTALLINE FORMS OF SGLT2 INHIBITORS | PCT/IB2012002852 | 2012-10-30 | WO2013064909A3 | 2013-08-22 | HENSCHKE JULIAN PAUL; HO MENG-FEN; CHEN SHU-PING; CHEN YUNG-FA |
| The present invention provides amorphous forms and the crystalline complexes of SGLT2 inhibitors as a novel material, in particular in pharmaceutically acceptable form. The crystalline forms of SGLT2 inhibitor canagliflozin are designated as Forms CS1, CS2, CS3, CS4 and CS5. | ||||||
QQ群二维码
意见反馈
意见反馈